- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00690703
Radiofrequency Ablation of Pulmonary Tumors Response Evaluation (RAPTURE)
June 4, 2008 updated by: Angiodynamics, Inc.
Radiofrequency Ablation of Pulmonary Tumors Response Evaluation: a Prospective, Intention-to-Treat, Multicenter Clinical Trial
The study hypothesis is that the radiofrequency (RF) ablation is a safe and effective treatment for malignant lung tumors.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Image-guided RF ablation is accepted as a viable therapeutic choice for patients with early-stage hepatocellular carcinoma or limited hepatic metastatic disease from colorectal cancer, when surgery is precluded (1, 2).
Recently, RF ablation has been proposed as a viable option for the treatment of pulmonary malignancies.
Experimental studies in animal tumor models have confirmed the effectiveness of RF ablation in the destruction of experimentally-induced pulmonary malignancies (3).
Pilot clinical investigations have suggested that the treatment can achieve high proportions of tumor response (4, 5).
We designed a prospective, intention-to-treat, multicenter clinical trial aimed at assessing feasibility, safety and effectiveness of RF ablation in the treatment of lung malignancies.
Study Type
Interventional
Enrollment (Actual)
106
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Sydney, Australia, NSW 2052
- University of New South Wales
-
-
-
-
-
Essen, Germany, 45122
- University Hospital Essen
-
Muenchen, Germany, 82152
- Ludwig-Maximilians University
-
-
-
-
-
Candiolo, Italy, 10060
- Institute for Cancer Research and Treatment
-
Pisa, Italy, 56100
- University of Pisa
-
-
-
-
-
London, United Kingdom, NW1 2BU
- University College Hospital
-
-
-
-
California
-
Los Angeles, California, United States, 90095
- UCLA Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- adult (> 18 years) male or female patient
- patient has biopsy-proven NSCLC or lung metastasis
- patient has been rejected for surgery and has been considered unfit for radiation therapy or chemotherapy
- patient has as many as 3 tumors per lung, each 3.5 cm or smaller in greatest diameter, by CT scan
- tumors are located at least 1 cm from trachea; main bronchi; esophagus; aorta; aortic arch branches; pulmonary artery; and heart
- tumors are accessible by percutaneous route
- patient has Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
- patient has platelet count > 100 x 109 /L and international normalized ratio ≤ 1.5
- patient has signed written informed consent prior to any study specific procedures.
Exclusion Criteria:
- patient has undergone previous pneumonectomy
- patient is considered at high-risk for RF ablation due to major co-morbid medical conditions
- patient has more than 3 tumors / lung
- patient has at least one tumor > 3.5 in greatest diameter
- tumor is associated with atelectasis or obstructive pneumonitis
- patient has renal failure requiring hemodialysis or peritoneal dialysis
- patient has active clinically serious infection
- patient has history of organ allograft
- patient has history of substance abuse or any medical, psychological or social conditions that may interfere with his / her participation in the study or evaluation of the study results
- patient is pregnant or breast-feeding
- patient has ECOG performance status > 2
- patient has platelet count ≤ 100 x 109 /L or international normalized ratio > 1.5.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
Treatment
|
computed tomography-guided RF ablation with an expandable electrode needle
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
complications
Time Frame: 30 days
|
30 days
|
technical success
Time Frame: immediate
|
immediate
|
pulmonary function
Time Frame: 2 years
|
2 years
|
tumor response
Time Frame: 1 years
|
1 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
overall survival
Time Frame: 2 years
|
2 years
|
quality of life
Time Frame: 2 years
|
2 years
|
cancer-specific survival
Time Frame: 2 years
|
2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Riccardo Lencioni, MD, University of Pisa, Pisa, Italy
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Tateishi R, Shiina S, Teratani T, Obi S, Sato S, Koike Y, Fujishima T, Yoshida H, Kawabe T, Omata M. Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases. Cancer. 2005 Mar 15;103(6):1201-9. doi: 10.1002/cncr.20892.
- Lencioni R, Cioni D, Crocetti L, Franchini C, Pina CD, Lera J, Bartolozzi C. Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. Radiology. 2005 Mar;234(3):961-7. doi: 10.1148/radiol.2343040350. Epub 2005 Jan 21.
- Simon CJ, Dupuy DE, DiPetrillo TA, Safran HP, Grieco CA, Ng T, Mayo-Smith WW. Pulmonary radiofrequency ablation: long-term safety and efficacy in 153 patients. Radiology. 2007 Apr;243(1):268-75. doi: 10.1148/radiol.2431060088.
- Miao Y, Ni Y, Bosmans H, Yu J, Vaninbroukx J, Dymarkowski S, Zhang H, Marchal G. Radiofrequency ablation for eradication of pulmonary tumor in rabbits. J Surg Res. 2001 Aug;99(2):265-71. doi: 10.1006/jsre.2001.6208.
- Pennathur A, Luketich JD, Abbas G, Chen M, Fernando HC, Gooding WE, Schuchert MJ, Gilbert S, Christie NA, Landreneau RJ. Radiofrequency ablation for the treatment of stage I non-small cell lung cancer in high-risk patients. J Thorac Cardiovasc Surg. 2007 Oct;134(4):857-64. doi: 10.1016/j.jtcvs.2007.04.060. Epub 2007 Aug 29.
- Lencioni R, Crocetti L, Cioni R, Suh R, Glenn D, Regge D, Helmberger T, Gillams AR, Frilling A, Ambrogi M, Bartolozzi C, Mussi A. Response to radiofrequency ablation of pulmonary tumours: a prospective, intention-to-treat, multicentre clinical trial (the RAPTURE study). Lancet Oncol. 2008 Jul;9(7):621-8. doi: 10.1016/S1470-2045(08)70155-4. Epub 2008 Jun 17.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2001
Primary Completion (Actual)
December 1, 2006
Study Completion (Actual)
December 1, 2007
Study Registration Dates
First Submitted
June 3, 2008
First Submitted That Met QC Criteria
June 4, 2008
First Posted (Estimate)
June 5, 2008
Study Record Updates
Last Update Posted (Estimate)
June 5, 2008
Last Update Submitted That Met QC Criteria
June 4, 2008
Last Verified
June 1, 2008
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 102-00
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Metastases
-
The First Affiliated Hospital of Guangzhou Medical...UnknownPulmonary Metastases | NSCLCChina
-
Azienda Sanitaria-Universitaria Integrata di UdineMaastricht UniversityUnknown
-
Masonic Cancer Center, University of MinnesotaWithdrawnPulmonary Metastases | Metastatic Melanoma | Brain Metastases | Hepatic MetastasesUnited States
-
University of PittsburghRITA Medical SystemsSuspendedPulmonary Metastases | NSCLCUnited States
-
Ruijin HospitalActive, not recruitingPulmonary Metastases | Osteosarcoma | ApatinibChina
-
Royal Marsden NHS Foundation TrustImperial College London; Royal Brompton & Harefield NHS Foundation Trust; Institute... and other collaboratorsRecruitingLung Cancer | Lung Metastases | Indeterminate Pulmonary Nodules | Second Primary CancerUnited Kingdom
-
Karolinska University HospitalKarolinska InstitutetActive, not recruiting
-
Zhejiang Cancer HospitalSecond Affiliated Hospital, School of Medicine, Zhejiang University; First... and other collaboratorsUnknownHepatocellular Carcinoma | Pulmonary Metastasis
-
Memorial Sloan Kettering Cancer CenterCompletedLung Metastases | Endobronchial Metastases | Pleural Metastases | Mediastinal MetastasesUnited States
-
Maria Sklodowska-Curie National Research Institute...RecruitingSoft Tissue Sarcoma | Pulmonary MetastasisPoland
Clinical Trials on RF ablation (Rita Medical Systems Model 1500x)
-
University of ArkansasDepartment of Health and Human Services; Ethicon Endo-Surgery; RITA Medical SystemsCompleted
-
Medtronic EndovascularVNUS Medical Technologies, A Covidien CompanyCompleted
-
Abbott Medical DevicesCompletedHypertensionAustralia, Greece
-
Dana-Farber Cancer InstituteNational Cancer Institute (NCI); National Institutes of Health (NIH)Completed
-
PossibleNational Institutes of Health (NIH); Brigham and Women's HospitalUnknownInfant Mortality | Under-two MortalityNepal